NSE: AUROPHARMA | BSE: 524804

Value Stock, Under Radar

Download real time

1147.80 -25.10 (-2.14%)

27.90% Fall from 52W High

2.0M NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

66,664.4

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Estimates Beat

Aurobindo Pharma's Q4FY25 revenue grows 10.4% YoY, beats Forecaster estimates by 2.8% See details

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Search Inside the pdf :

Aurobindo Pharma Ltd.

28 May 2025

1147.80

-2.14%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Axis Direct

We maintain our BUY recommendation on Aurobindo Pharma with a TP of Rs 1,500/share.

Aurobindo Pharma Ltd.'s price crossed below 100Day SMA today

Aurobindo Pharma Ltd.

27 May 2025

1147.80

-2.14%

Aurobindo Pharma (ARBP IN) Q4FY25 Result Update Resumption...

Buy: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

Aurobindo Pharma's (ARBP) Q4FY25 EBITDA of Rs17.9bn (up 6% YoY) was in line with our estimate. FY26 guidance of high single digit revenue growth ex gRevlimid with flat margins was below our estimate. Resultant our FY26 and FY27E EPS stands reduced by 4-5%. Other expenses remained elevated on the back of higher PenG-related operational cost and supply disruptions due to...

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

19 Apr 2025

1147.80

-2.14%

Aurobindo Pharma Ltd Tgt 1359

Buy: Aurobindo Pharma Ltd.

Target

BP Wealth

Aurobindo Pharma Ltd.'s price crossed below 100Day SMA today

Aurobindo Pharma Ltd.

17 Mar 2025

1147.80

-2.14%

Aurobindo Pharma (BUY): Growth triggers intact; valuations attractive

Buy: Aurobindo Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Eugia unit 3 capacity utilization to increase to 60-65% from 50% in Q3FY25. We expect capacity utilisation to rise above 70% in FY26E

Aurobindo Pharma Ltd. has an average target of 1493.80 from 10 brokers.

Aurobindo Pharma Ltd.

10 Feb 2025

1147.80

-2.14%

AUROBINDO PHARMA

Buy: Aurobindo Pharma Ltd.

Recommendation Target

Prabhudas Lilladhar

Promoters unpledged 0.91% of shares in last quarter. Total pledge stands at 16.92% of promoter holdings

Aurobindo Pharma Ltd.

10 Feb 2025

1147.80

-2.14%

Volume growth and complex generics will aid growth

Buy: Aurobindo Pharma Ltd.

KRChoksey

Aurobindo Pharma’s revenue beat our estimates (+2.8%) due to strong performance in Europe and Growth markets. EBITDA beat our estimates (+4.4%) due to better than expected gross profit and Adj. PAT beat our estimates due to better than expected other income and lower than expected tax expense.

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

10 Feb 2025

1147.80

-2.14%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We maintain our BUY recommendation on Aurobindo Pharma with a target price of Rs 1,500/share

Number of FII/FPI investors decreased from 730 to 724 in Mar 2025 qtr

Aurobindo Pharma Ltd.

08 Feb 2025

1147.80

-2.14%

Soft quarter; growth levers intact

Buy: Aurobindo Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Aurobindo Pharma’s Q3FY25 performance was below our expectation due to lower-than-anticipated sales in US while Europe (up 22.7% YoY) and growth markets (up 39.2% YoY) maintained traction. EBITDA margin was 20.4% despite lower gRevlimid sales and INR 600mn cost of Pen-G plant.